Welcome to our dedicated page for AbbVie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on AbbVie stock.
AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
West (NYSE: WST) agreed to sell all manufacturing and supply rights for the SmartDose 3.5mL On-Body Delivery System and associated facilities to AbbVie (NYSE: ABBV) for $112.5 million at close, subject to working capital and other adjustments.
The definitive agreement is subject to closing conditions and is expected to close in mid-2026. West will continue commercial supply and execute ongoing project commitments prior to close, which may include milestone-based payments before closing.
SmartDose 3.5mL revenues represented approximately 4% of fiscal 2025 revenue. West said it will provide more details when it issues 2026 guidance on its Q4 2025 earnings call in February. The company will continue development and manufacture of other SmartDose products, including the SmartDose 10mL system.
AbbVie (NYSE:ABBV) agreed to acquire a device manufacturing facility and associated intellectual property from West Pharmaceutical Services (NYSE:WST) in Tempe, Arizona, expanding its drug delivery device manufacturing capacity.
AbbVie plans to hire approximately 200 employees at the site and to invest more than $175 million to acquire, modernize, and integrate the facility into its global network. The deal transfers multiple production lines and 3.5 mL on-body injector technology to support current and next-generation immunology and neuroscience medicines. The transaction is anticipated to close in mid-2026, subject to closing conditions, and is part of AbbVie's broader plan to invest >$10 billion in U.S. capital over the next decade.
AbbVie (NYSE: ABBV) will report full-year and fourth-quarter 2025 financial results on Wednesday, February 4, 2026, before the market opens. The company will host a live webcast of the earnings conference call at 8:00 a.m. Central time accessible via its investor relations site at investors.abbvie.com. An archived edition of the session will be available later that day.
AbbVie (NYSE: ABBV) will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026. Management will participate in a fireside chat at 10:15 a.m. Central time.
A live audio webcast will be accessible via AbbVie’s Investor Relations website at investors.abbvie.com, and an archived edition of the session will be available later the same day.
AbbVie (NYSE: ABBV) will present new ASH 2025 data across multiple blood cancers, including MM, FL, CLL, DLBCL, AML and AL. Key trial highlights include EPCORE FL-1 phase 3 results showing PFS HR 0.21 (79% risk reduction) and ORR 95.7% for epcoritamab+R2 vs 81.0% with R2; CLL17 fixed-duration venetoclax arms meeting non-inferiority versus ibrutinib with ~3-year PFS ≈81%; etentamig (ABBV-383) combination ORR 81% in heavily pretreated MM; and PVEK+VEN+AZA CR rate 63.3% in newly diagnosed AML unfit for intensive chemo.
Safety signals include higher grade 3/4 neutropenia and infections across several regimens; investigational agents remain under study.
AbbVie (NYSE: ABBV) will present at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025. Management will take part in a fireside chat at 7:30 a.m. Central time. A live audio webcast will be available via AbbVie's investor relations site, and an archived recording will be posted later the same day.
AbbVie (NYSE: ABBV) announced U.S. FDA approval of EPKINLY (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) for adult patients with relapsed or refractory follicular lymphoma after ≥1 prior systemic therapy.
The approval follows Phase 3 EPCORE FL-1 where EPKINLY + R2 reduced risk of progression or death by 79% (HR 0.21), achieved 89% ORR and 74% complete response, and median PFS was not reached versus 11.2 months for R2. Safety was consistent with known profiles; CRS occurred in 24% (mostly Grade 1–2).
AbbVie (NYSE: ABBV) launched Second Winds, a short film about three people living with chronic lymphocytic leukemia (CLL). The film premiered on Nov 13, 2025 in Los Angeles hosted by Jesse Tyler Ferguson and is announced on Nov 14, 2025. It follows Christina, Jeff, and Alejandro and highlights resilience, community support, and quality of life.
Key cited figures: about 226,432 people with CLL in the U.S. (2022) and an estimated 23,000 new cases expected in 2025. The film is available on LA Times Studios Short Docs and AbbVie YouTube and will stream on Documentary+ in December 2025.
AbbVie (NYSE: ABBV) announced the 20 recipients of the 2025 AbbVie Migraine Career Catalyst Award™, providing each winner with $2,500 to support career development for people living with migraine. The program highlights workplace impact from migraine—noting presenteeism accounts for nearly 90% of migraine-related productivity loss—and showcases winners from diverse professions who shared stories of resilience and career disruption. The company reiterated its portfolio of three migraine treatment options and ongoing research efforts.
Allergan Aesthetics (NYSE: ABBV) will present clinical and real‑world data at the 2025 American Society for Dermatologic Surgery Annual Meeting, Nov 13–16, 2025, in Chicago. The company submitted 17 abstracts, including three oral presentations in the Cosmetic "Top Ten" session on Nov 13 highlighting Phase 3 results for first‑in‑class trenibotulinumtoxinE and a Phase 4 study of 64 units of BOTOX Cosmetic for upper facial lines.
Sessions include expert panels on hyaluronic acid fillers and a symposium on the newest BOTOX Cosmetic indication for platysma bands, plus video posters covering safety, efficacy, and patient‑reported outcomes across the portfolio.